STD News

STDs in Women: Often Silent, Sometimes Severe

April 6th, 2011  |  Published in STD News

STDs in women are a major cause of chronic health issues in females.  Though some common STDs can be treated and cured if caught early on, undiagnosed STDs in women have the potential to cause irreversible damage for those infected. According to the U.S. CDC, women are more likely than men to contract certain STDs due to their anatomy, including Chlamydia, genital herpes, and HPV. For this reason, annual testing is strongly encouraged to halt the spread of STDs in women.

Chlamydia in Women

Chlamydia is the country’s most prevalent STD. In 2008, over 1.2 million new cases of Chlamydia infection were reported, the majority of which affected females. Some common signs of Chlamydia in women can include abnormal white or yellow vaginal discharge, pain during urination, and overall genital pain. Bleeding in between menstrual periods has also been noted as one of the signs of Chlamydia in women.

Though some affected females will notice symptoms within two to four weeks following exposure, an overwhelming 75 percent of those infected will never experience symptoms. For this reason, Chlamydia is considered one of the most dangerous STDs in women. Though the disease is easily curable, when left undetected, Chlamydia can result in chronic pelvic pain, permanent reproductive damage, infertility, and potentially deadly ectopic pregnancies. Unfortunately, many infected women won’t experience initial symptoms and will therefore neglect to get tested until long-term effects have set in. To prevent this, the CDC recommends annual Chlamydia testing.

Common misspellings for chlamydia include klamydia, clamidia, chlamidia, and klamidia.

HPV Virus in women

Though both males and females are at risk for contracting the HPV virus, in women, it can actually be deadly. Certain strains of HPV have been linked to cervical cancer, which is a severe health concern in women. HPV can cause genital warts in some strains but most HPV strains do not produce noticeable symptoms, regular testing is crucial for women at risk. The CDC recommends screening once a year at a minimum, usually in conjunction with an annual gynecological exam. However, an FDA-approved vaccine can prevent against the four strains of HPV that cause cervical cancer and genital warts.

Genital Herpes in Women

The CDC reports that women are almost twice as likely to contract genital herpes as men, making it one of the most widespread STDs in women. One in five sexually active women is positive for genital herpes. While some infected women will experience symptoms such as severely painful genital sores and vaginal discomfort within the first few weeks following infection, others may never display signs of genital herpes at all. Some may experience symptoms so mild they are mistaken for benign conditions such as shaving irritation, a skin rash, or a yeast infection.

Though herpes itself isn’t known to be fatal, its presence does put those infected at risk for additional STDs in women, including HIV. Additionally, since herpes can’t be cured and may be transmitted to a newborn during childbirth, the disease is considered to be one of the most problematic STDs in women.

Understanding STDs in Women

On a whole, sexually active women are more likely to contract STDs than men, and the reason has to do with basic female anatomy. Compared to males, the female genital region provides a more conducive environment to harbor STD-causing bacteria. STDs in women are a particular concern for females under 25 since their cervixes are less developed and therefore more susceptible to infection and long-term damage.

Protecting Women from STDs

To address the problem of STDs in women, the CDC recommends annual screenings and safe sexual practices. Certain STDs in women, including Chlamydia, can be cured, while others can be managed to minimize long-term damage. The key is to become aware of infection before permanent consequences set in.

In the News: HPV Testing for Both Men and Women

November 10th, 2010  |  Published in STD News

While the Centers for Disease and Control (CDC) currently recommends the HPV vaccine for all girls and women ages 11 to 26, U.S. health experts are now debating making the vaccine routine for boys and men as well.

HPV, or the human paillomavirus, is a common sexually transmitted disease that can cause cervical cancer and genital warts. The vaccine protects against four strains of HPV which cause 90% of genital warts and 75% of cervical cancer cases. HPV most frequently causes cervical cancer, but it has also been linked to penile cancer and certain cancers of the head and throat. The vaccine also protects against two strains of HPV that cause approximately 80% of anal cancer cases.

It may seem obvious to immunize both sexes against a disease that causes cancer, but the debate is complicated. One main issue revolves around whether the vaccine is too expensive to justify its use with each of the three required doses costing $108. According to one study, the vaccination rate in women is already low, so vaccinating males would not be as cost effective as a program working to improve immunization rates for women. This study also suggests that when vaccination rates are high among women, immunizing men is not cost effective.

However, with an increased frequency of anal cancer and its link to HPV, supporters of the vaccine stress the importance of vaccinating both women and men, particularly men who have sex with other men. Anal cancer rates are higher among men who have sex with other men, and there is currently no routine screening program in place for early detection like cervical cancer. This vaccine is a rare cancer-prevention opportunity, and while the technology is available, experts are debating the best way to implement and distribute the HPV vaccine.

If this vaccine was made more prevalent, there would be specific recommendations for homosexual and bisexual men. Some experts say it would be important to make this vaccine routine at a young age and vaccinate all boys before they become sexually active, around ages 11 to 12, so they would not have to disclose their sexual orientation. However, specifically targeting this high-risk segment would be the most cost-effective approach.

Research confirms the vaccine’s health benefits, and as of October 2009, one HPV vaccine, Gardasil, was deemed to be safe and approved by the Food and Drug Administration (FDA) for the use in boys and men ages 9 to 26. Yet, despite its medical contributions, there is still much debate on how to administer the vaccine. Currently, less than 1% of boys ages 11 to 17 are protected against HPV, and about 15% of men on college campuses are vaccinated.

Sources: gardasil.com/what-is-gardasil/information-on-gardasil/index.html#three

health.yahoo.net/news/s/nm/us_cancer_hpv_vaccine?utm_source=twitterfeed&utm_medium=twitter

nytimes.com/2010/10/29/us/29vaccine.html?_r=1

webmd.com/cancer/news/20101102/hpv-vaccine-costeffective-way-to-prevent-anal-cancer